Current partner codePEPTIDESDE
NCT04049760·Phase 3·INTERVENTIONAL

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Status

Completed

Phase

Phase 3

Enrollment

16

Locations

6

Results

Posted

Publications

0

Study summary

What the protocol is testing.

This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \> 12 Years of Age With Fabry Disease and Amenable GLA Variants

Interventions

Treatment arms and agents.

DRUG

migalastat HCl 150 mg

migalastat HCl 150 mg capsule

Timeline

From registration to results.

  1. First posted

    Aug 8, 2019

  2. Study start

    Oct 11, 2019

  3. Primary completion

    Nov 29, 2024

  4. Study completion

    Nov 29, 2024

  5. Results posted

    Jun 17, 2025

  6. Registry updated

    Feb 5, 2026

Outcomes

What the study measures.

Primary outcomes

Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug

Time frame · Entire study

Number of subjects with TEAE, SAE, and AE leading to discontinuation during the study period

Secondary outcomes

Change From Baseline to Month 24 in Estimated Glomerular Filtration Rate (eGFR)

Time frame · Baseline, Month 24

Estimated GFR was calculated using the modified Schwartz formula according to the standards of the central laboratory.

Change From Baseline to Month 24 in Urine Protein Levels

Time frame · Baseline, Month 24

Renal function was assessed by urine protein levels (mg/L). Urine samples were collected as part of urinalysis.

Change From Baseline to Month 24 in Urine Albumin

Time frame · Baseline, Month 24

Renal function was assessed by urine albumin levels (mg/L). Urine samples were collected as part of urinalysis

Change From Baseline to Month 24 in Left Ventricular Mass Index (LVMi)

Time frame · Baseline, Month 24

LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M-mode and 2D views are presented.

Change From Baseline to Month 24 in Pediatric and Quality of Life Inventory™ (PedsQL™) Scores

Time frame · Baseline, Month 24

The Pediatric Quality of Life Inventory (PedsQL™) was a modular approach to measuring health-related quality of life (QoL) in healthy children and adolescents and those with acute and chronic health conditions. All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0 to 100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Psychosocial, physical, and total scores were calculated based on the response to the questions within the patient reported outcome. The psychosocial score for the PedsQL encompassed 15 questions relating to the subjects' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the subjects' ease of managing physical activity. Total scores were the sum of all the item scores over the number of items answered on all the scales. Change from baseline values of \<0 represents worsening, 0 equals no change, and \>0 represents improvement.

Change From Baseline to Month 24 in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) Score for Pain Intensity

Time frame · Baseline, Month 24

The Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ) included questions about Fabry disease-specific symptoms. The assessment of "How bad is your pain today?" was measured on a 10- point scale from 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.

Number of Subjects Who Experienced Sudden Onset of Pain As Assessed Using the Fabry-Specific Health and Pain Questionnaire (FPHPQ)

Time frame · Month 24

Subjects were asked "In the last 3 months how many times did you experience sudden onset of pain?" and responses were reported in the FPHPQ. Responses were categorized as 0, 1 to 3, 4 to 6, and \> 6 occurrences of sudden onset of pain.

Change From Baseline to Month 24 in Plasma Levels of Lyso-Gb3

Time frame · Baseline, Month 24

Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.

Eligibility

Who can take part.

Minimum age
12 Years
Maximum age
17 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Male or female subjects diagnosed with Fabry disease \> 12 years of age who completed Study AT1001-020 * Subject's parent or legally-authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of personal health information or research-related health information, and subject provides assent, if applicable * If of reproductive potential, both male and female subjects agreed to use a medically accepted method of contraception throughout the duration of the study and for up to 30 days after their last dose of migalastat Exclusion Criteria: * Subject's last available estimated glomerular filtration rate (eGFR) in the previous study was \< 60 mL/min/1.73 m2 * Subject had advanced kidney disease requiring dialysis or kidney transplantation * Subject received any investigational/experimental drug, biologic, or device within 30 days before baseline, with the exception of migalastat * Subject anticipated starting gene therapy during the study period * Subject had any intercurrent illness or condition at Visit 1 that may have precluded the subject from fulfilling the protocol requirements or suggested to the investigator that the potential subject may have an unacceptable risk by participating in this study * Subject had a history of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol) * Subject required treatment with Replagal® (agalsidase alfa) or Fabrazyme® (agalsidase beta) * Subject required treatment with Glyset® (miglitol) or Zavesca® (miglustat) * Female subject was pregnant or breast-feeding, or was planning to become pregnant during the study period * In the opinion of the investigator, the subject and/or parent or legally-authorized representative was unlikely or unable to comply with the study requirements

Study locations

6 registered sites.

United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.

University of South Florida

Tampa, Florida, United States

The Emory Clinic

Atlanta, Georgia, United States

University of Minnesota Masonic Children's Hospital and Clinics

Minneapolis, Minnesota, United States

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Lysosomal & Rare Disorders Research & Treatment Center

Fairfax, Virginia, United States

Royal Free London NHS Foundation Trust

London, United Kingdom

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Larazotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.